Ma Wangbin, Liu Rongqiang, Wang Jianguo, Liu Li, Qiu Zhendong, Yu Jia, Wang Weixing
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
PLoS One. 2024 Aug 8;19(8):e0308570. doi: 10.1371/journal.pone.0308570. eCollection 2024.
Tumor burden score (TBS) based on maximum tumor diameter and number has been shown to correlate with prognosis in patients with hepatocellular carcinoma (HCC). Nevertheless, the results are conflicting. Hence, we conducted a meta-analysis to analyze the association between TBS and survival outcomes of HCC patients.
A comprehensively search of the databases including PubMed, Embase and Web of Science was performed to retrieve studies satisfying the inclusion criteria until August 31, 2023. The hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. All the data analyses were carried out by STATA 12.0.
10 retrospective studies containing 25073 patients were incorporated in the study. The results demonstrated that high TBS was markedly association with poor overall survival (OS) (HR: 1.79, 95% CI: 1.45-2.23) and relapse-free survival / progression-free survival(RFS/PFS) (HR: 1.71; 95% CI: 1.42-2.07). Subgroup analysis showed that the prognostic value of TBS in HCC was not affected by any subgroup.
TBS may be an efficient prognostic index in HCC patients.
基于最大肿瘤直径和数量的肿瘤负荷评分（TBS）已被证明与肝细胞癌（HCC）患者的预后相关。然而，结果存在冲突。因此，我们进行了一项荟萃分析，以分析TBS与HCC患者生存结局之间的关联。
全面检索包括PubMed、Embase和Web of Science在内的数据库，以检索符合纳入标准的研究，检索截至2023年8月31日。计算风险比（HRs）和95%置信区间（CIs）。所有数据分析均使用STATA 12.0进行。
该研究纳入了10项包含25073例患者的回顾性研究。结果表明，高TBS与较差的总生存期（OS）（HR：1.79，95%CI：1.45-2.23）和无复发生存期/无进展生存期（RFS/PFS）（HR：1.71；95%CI：1.42-2.07）显著相关。亚组分析表明，TBS在HCC中的预后价值不受任何亚组的影响。
TBS可能是HCC患者的一个有效预后指标。
